Oncotarget:PRPF的超表达可以通过肌动蛋白细胞骨架重排和上皮间质转化诱导抗药性产生

2017-06-06 AlexYang MedSci原创

mRNA前体加工因子(PRPF)4B激酶属于类CDK激酶家族成员,并且参与mRNA前体剪切和信号转导。最近,有研究人员观察到了PRPF的超表达可以减少细胞内活性氧种类水平,并且在HCT116人类结肠癌细胞中,可以通过激活细胞存活信号蛋白 NFκB,、ERK、 和 c-MYC抑制白藜芦醇诱导的细胞凋亡。研究发现,PRPF的超表达改变了细胞学形态,并且通过调控Rho家族蛋白的活性,实现对肌动蛋白细胞骨

mRNA前体加工因子(PRPF)4B激酶属于类CDK激酶家族成员,并且参与mRNA前体剪切和信号转导。最近,有研究人员观察到了PRPF的超表达可以减少细胞内活性氧种类水平,并且在HCT116人类结肠癌细胞中,可以通过激活细胞存活信号蛋白 NFκB,、ERK、 和 c-MYC抑制白藜芦醇诱导的细胞凋亡。

研究发现,PRPF的超表达改变了细胞学形态,并且通过调控Rho家族蛋白的活性,实现对肌动蛋白细胞骨架的重排。更多的是,PRPF超表达减少了RhoA的活性,但是却增加了Rac1的表达。另外,PRPF超表达刺激了上皮间质转化(EMT),并且减少了HCT116、PC3人类前列腺和B16-F10黑色素瘤细胞的侵入性。另外,E-钙黏蛋白的缺失、EMT标志物在HCT116细胞超表达PRPF中观察到。总之,这些结果表明了PRPF通过激活细胞生存信号通路,阻碍了白藜芦醇诱导的凋亡作用,并且对肌动蛋白细胞骨架进行了重排,诱导了EMT的发生。最后,研究人员指出,对该机制的阐明为抗癌药物抗性打下了基础,并且PRPF的抗凋亡作用也许可以在各种癌症中的抑制肿瘤生长和阻止转移中,提供一种新的治疗方法基础。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1992842, encodeId=e3f719928426c, content=<a href='/topic/show?id=1c5780908fc' target=_blank style='color:#2F92EE;'>#肌动蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80908, encryptionId=1c5780908fc, topicName=肌动蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Tue Jul 18 10:47:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704941, encodeId=a7cd1e04941a1, content=<a href='/topic/show?id=7b3c20040c8' target=_blank style='color:#2F92EE;'>#上皮间质转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20040, encryptionId=7b3c20040c8, topicName=上皮间质转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9530903442, createdName=limedical1984, createdTime=Tue Sep 12 04:47:00 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958330, encodeId=26951958330c1, content=<a href='/topic/show?id=3f5514e764a' target=_blank style='color:#2F92EE;'>#PRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14776, encryptionId=3f5514e764a, topicName=PRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Feb 03 18:47:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795367, encodeId=825f1e9536723, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jan 28 07:47:00 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495377, encodeId=46fe14953e748, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Jun 08 12:47:00 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1992842, encodeId=e3f719928426c, content=<a href='/topic/show?id=1c5780908fc' target=_blank style='color:#2F92EE;'>#肌动蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80908, encryptionId=1c5780908fc, topicName=肌动蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Tue Jul 18 10:47:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704941, encodeId=a7cd1e04941a1, content=<a href='/topic/show?id=7b3c20040c8' target=_blank style='color:#2F92EE;'>#上皮间质转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20040, encryptionId=7b3c20040c8, topicName=上皮间质转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9530903442, createdName=limedical1984, createdTime=Tue Sep 12 04:47:00 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958330, encodeId=26951958330c1, content=<a href='/topic/show?id=3f5514e764a' target=_blank style='color:#2F92EE;'>#PRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14776, encryptionId=3f5514e764a, topicName=PRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Feb 03 18:47:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795367, encodeId=825f1e9536723, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jan 28 07:47:00 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495377, encodeId=46fe14953e748, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Jun 08 12:47:00 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1992842, encodeId=e3f719928426c, content=<a href='/topic/show?id=1c5780908fc' target=_blank style='color:#2F92EE;'>#肌动蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80908, encryptionId=1c5780908fc, topicName=肌动蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Tue Jul 18 10:47:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704941, encodeId=a7cd1e04941a1, content=<a href='/topic/show?id=7b3c20040c8' target=_blank style='color:#2F92EE;'>#上皮间质转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20040, encryptionId=7b3c20040c8, topicName=上皮间质转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9530903442, createdName=limedical1984, createdTime=Tue Sep 12 04:47:00 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958330, encodeId=26951958330c1, content=<a href='/topic/show?id=3f5514e764a' target=_blank style='color:#2F92EE;'>#PRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14776, encryptionId=3f5514e764a, topicName=PRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Feb 03 18:47:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795367, encodeId=825f1e9536723, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jan 28 07:47:00 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495377, encodeId=46fe14953e748, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Jun 08 12:47:00 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1992842, encodeId=e3f719928426c, content=<a href='/topic/show?id=1c5780908fc' target=_blank style='color:#2F92EE;'>#肌动蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80908, encryptionId=1c5780908fc, topicName=肌动蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Tue Jul 18 10:47:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704941, encodeId=a7cd1e04941a1, content=<a href='/topic/show?id=7b3c20040c8' target=_blank style='color:#2F92EE;'>#上皮间质转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20040, encryptionId=7b3c20040c8, topicName=上皮间质转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9530903442, createdName=limedical1984, createdTime=Tue Sep 12 04:47:00 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958330, encodeId=26951958330c1, content=<a href='/topic/show?id=3f5514e764a' target=_blank style='color:#2F92EE;'>#PRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14776, encryptionId=3f5514e764a, topicName=PRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Feb 03 18:47:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795367, encodeId=825f1e9536723, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jan 28 07:47:00 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495377, encodeId=46fe14953e748, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Jun 08 12:47:00 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
    2018-01-28 闆锋旦
  5. [GetPortalCommentsPageByObjectIdResponse(id=1992842, encodeId=e3f719928426c, content=<a href='/topic/show?id=1c5780908fc' target=_blank style='color:#2F92EE;'>#肌动蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80908, encryptionId=1c5780908fc, topicName=肌动蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca6a2500099, createdName=more is better!, createdTime=Tue Jul 18 10:47:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704941, encodeId=a7cd1e04941a1, content=<a href='/topic/show?id=7b3c20040c8' target=_blank style='color:#2F92EE;'>#上皮间质转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20040, encryptionId=7b3c20040c8, topicName=上皮间质转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd9530903442, createdName=limedical1984, createdTime=Tue Sep 12 04:47:00 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958330, encodeId=26951958330c1, content=<a href='/topic/show?id=3f5514e764a' target=_blank style='color:#2F92EE;'>#PRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14776, encryptionId=3f5514e764a, topicName=PRP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Sat Feb 03 18:47:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795367, encodeId=825f1e9536723, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jan 28 07:47:00 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495377, encodeId=46fe14953e748, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Jun 08 12:47:00 CST 2017, time=2017-06-08, status=1, ipAttribution=)]
    2017-06-08 songbq

相关资讯

ASCO2017:肿瘤脑转移患者生存期影响因素

肿瘤脑转移病灶数目与患者生存期密切相关,大部分患者不受颅内疾病体积影响,肿瘤突变亚型对脑转移患者的生存期影响不显著

Haematologica:经伊马替尼治疗的慢性粒细胞白血病患者第二个原发恶性肿瘤发病率及相关死亡率如何?

总之,研究人员发现采用伊马替尼治疗的慢性髓细胞白血病患者没有显示出有较高的第二个原发恶性肿瘤的发病率,但是,第二个原发恶性肿瘤的结局比预期更糟糕。

CELL REP:致癌代谢物 2-HG 通过下调 RIP3 促进肿瘤生成

国际知名学术刊物《Cell Reports》在线发表了韩家淮教授课题组和李勤喜课题组的最新合作研究成果“2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter”,揭示了IDH1 R132突变体产生的致癌代谢物2-HG会促进DNMT1与RIP3启动子区域的结合,导致R

ASCO 2017:热点聚焦——新药Larotrectinib(LOXO-101)治疗各种成人及儿童癌症效果卓越

每年的ASCO大会都会有公司一夜爆红。今年,一家名为Loxo的小公司因其核心在研药物larotrectinib(LOXO-101)的早期临床数据成为了ASCO 2017大会上的一匹黑马。larotrectinib是作为一款广谱肿瘤药来开发,拟用于所有表达有原肌球蛋白受体激酶( tropomyosin receptor kinase,TRK)的肿瘤患者,而不是针对某个解剖位置的肿瘤。TRK融合广泛分

ASCO2017:人类肿瘤异种疫苗可治疗多种癌症

Bi-vaccine疫苗表现出对多种癌症的治疗能力,有望成为针对所有肿瘤治疗的新武器

Cancer Res:“饿死”癌细胞的新策略研究获取重要进展!

为了努力使大脑癌细胞挨饿,并对肿瘤发展进行制动,北卡罗莱纳大学治疗综合性癌症中心研究人员阻止了脑肿瘤细胞用于将糖转化为能量的主要途径。他们希望这会使肿瘤细胞饥饿,并减缓其生长。令人吃惊的是,该策略实际上加速了成神经管细胞瘤实验室模型的增长。